Form 4: SAB Biotherapeutics CMO Reports RSU Tax Withholding

SAB Biotherapeutics' Chief Medical Officer, Alexandra Kropotova, reported a transaction involving shares withheld for tax obligations related to restricted stock unit vesting.

Summary

• Alexandra Kropotova, Chief Medical Officer of SAB Biotherapeutics, Inc. (SABS), reported a change in beneficial ownership.
• The transaction involved the disposition of 988 shares of Common Stock.
• These shares were withheld to satisfy tax withholding requirements upon the vesting of the Issuer's restricted stock units (RSUs).
• Following this transaction, Ms. Kropotova beneficially owns 44,284 shares of Common Stock.
• This total includes 31,946 shares of Common Stock and 12,338 shares of Common Stock which remain subject to vesting of RSUs granted under the Issuer's 2021 Equity Incentive Plan, as amended.
• Each RSU represents a contingent right to receive one share of Common Stock.
• The transaction date was December 11, 2025.

Sentiment

Score: 5

Explanation: This is a standard Form 4 filing reporting a tax-related share withholding upon RSU vesting, which is a neutral event from a market sentiment perspective. It reflects a routine compensation event rather than operational performance or strategic shifts.

Positives

• The vesting of Restricted Stock Units (RSUs) indicates the achievement of performance or service conditions by the Chief Medical Officer, reflecting continued executive engagement and retention.

Negatives

• 988 shares of common stock were disposed of (withheld) to cover tax obligations, resulting in a minor reduction in the direct share count held by the insider.

Future Outlook

This Form 4 filing reports a past transaction and does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This is a routine insider transaction filing (Form 4) related to executive compensation and tax obligations, which typically does not reflect broader industry trends or competitive dynamics.

Stakeholder Impact

• Shareholders: A minor reduction in direct beneficial ownership by a key executive due to tax withholding, which is a routine event and generally has minimal impact on overall shareholder value or perception.

Key Dates

Keywords

SAB Biotherapeutics, SABS, Form 4, insider transaction, RSU vesting, tax withholding, beneficial ownership, Alexandra Kropotova, Chief Medical Officer